Company intelligence / Profile preview

Valley Forge

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Valley Forge Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative topical therapies for vision-threatening ophthalmic diseases. The company's lead candidate, VFP-101, is a proprietary small molecule eye drop designed to treat dry Age-related Macular Degeneration (dry AMD) and geographic atrophy. By offering a non-invasive, topical alternative to current intravitreal injections, Valley Forge aims to improve patient compliance and outcomes in the treatment of progressive retinal conditions. The company is led by a team of experienced ophthalmologists and drug development experts focused on addressing significant unmet needs in the vision care market.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Valley Forge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valley Forge.

Explore the full profile